A new COVID-19 variant, BA.3.2, is circulating in the U.S. and sparking conversation online. The variant, which was first detected in South Africa in November 2024, was overtaken by other variants before reemerging late last year. This unusual pattern earned it the nickname “Cicada.” BA.3.2 is rising in Europe, and experts expect U.S. cases to follow. Early reports suggest that children may be up to five times more likely to catch BA.3.2 than previous variants.
The highly mutated variant has been the topic of widespread news coverage and online conversations. Many posts showed little concern about COVID-19, with some suggesting the symptoms are likely a cold, the flu, or allergies. Others claimed vaccination is ineffective and promoted conspiracy theories that the variant is a “distraction” from the upcoming U.S. midterm election or the Iran War. Several posts expressed concern that BA.3.2 may affect children more than previous variants, although some dismissed this as “propaganda” and “fear-mongering.”
Recommendation
Reports of emerging COVID-19 variants provide an opportunity to clear up confusion and share information about protecting individuals and communities. Messaging may explain that BA.3.2 is part of the Omicron family of viruses that scientists have tracked for over four years and that current vaccines, tests, and treatments are designed to target.
Highlighting that BA.3.2 symptoms are the same as previous variants (runny or stuffy nose; fever or chills; sore throat; headache; cough; and body aches) is recommended, as is explaining that there is currently no evidence that BA.3.2 is more severe or contagious than recent dominant strains.
Health communicators may emphasize that experts say BA.3.2 may be better able to evade immunity from vaccination or infections, but the updated 2025–2026 COVID-19 vaccine should remain effective against severe illness. Additionally, messaging may clarify that COVID-19 tests should still detect the variant.
Fact-checking sources: PolitiFact, Time
Communication resources: Find more talking points for communicating about COVID-19
